Hormonal carcinogenesis

Carcinogenesis

Volumn 21, Issue 3, 2000, Pages 427-433

  Henderson, Brian E ^a   Feigelson, Heather Spencer ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN RECEPTOR; AROMATASE; CYTOCHROME P450 ISOENZYME; ESTROGEN; ESTROGEN RECEPTOR ALPHA; FINASTERIDE; PROGESTERONE; STEROID 5ALPHA REDUCTASE; TAMOXIFEN; TESTOSTERONE 17BETA DEHYDROGENASE;

BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; ENDOMETRIUM CANCER; HORMONAL CARCINOGENESIS; HORMONE METABOLISM; HORMONE SUBSTITUTION; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0034099083     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/21.3.427     Document Type: Review

References (68)

1. Henderson, B.E., Ross, R.K., Pike, M.C. and Cassagrande, J.T. (1982) Endogenous hormones as a major factor in human cancer. Cancer Res., 24, 3232-3239.
2. Henderson, B.E., Ross, R.K. and Bernstein, L. (1988) Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res., 48, 246.
3. Feigelson, H.S., Ross, R.K., Yu, M.C., Coetzee, G.A., Reichardt, J.K.V. and Henderson, B.E. (1996) Genetic susceptibility to cancer from exogenous and endogenous exposures. J. Cell Biochem., 25S, 15-22.
4. Ross, R.K., Pike, M.C., Coetzee, G.A., Reichardt, J.K.V., Yu, M.C., Feigelson, H., Stanczyk, F.Z., Kolonel, L.N. and Henderson, B.E. (1998) Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res., 58, 4497-4504.
5. Sager, R. (1989) Tumor-suppressor genes: The puzzle and the promise. Science, 246, 1406.
6. Stanbridge, E. (1990) Identifying tumor-suppressor genes in human colorectal cancer. Science, 247, 12.
7. Knudson, A. (1971) Mutation and cancer: Statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA, 68, 820.
8. Mikki, Y., Swensen, D., Shattuck-Eidens, P.A. et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266, 66-71.
9. Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C. and Micklem, G. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature, 378, 789-792.
10. Li, F.P. (1996) Familial aggregation. In Schottenfeld, D. and Fraumeni, J.F. (eds) Cancer Epidemiology and Prevention. 2nd edn. Oxford University Press, New York, NY, pp. 546-558.
11. Pietras, R.J. and Pegram, M.D. (1999) Oncogene activation and breast cancer progression. In Manni, A. (ed.) Endocrinology of Breast Cancer. Humana Press, NJ, pp. 133-154.
12. Key, T.J.A. and Pike, M.C. (1988) The dose-effect relationship between 'unopposed' estrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br. J. Cancer. 57, 205.
13. Henderson, B.E., Bernstein, L. and Ross, R. (1997) Etiology of cancer: hormonal factors. In DeVita, V.T., Hellman, S. and Rosenberg, S.A. (eds) Cancer: Principles and Practice of Oncology. 5th edn. Lippincott-Raven, PA, pp. 219-229.
14. Weiss, N.S., Szekely, D.R. and Austin, D.F. (1976) Increasing incidence of endometrial cancer in the United States. N. Engl. J. Med., 294, 1259-1262.
15. Anonymous (1987) Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA, 257, 796-800.
16. Henderson, B.E., Casagrande, J.T., Pike, M.C., Mack, T., Rosario, I. and Duke, A. (1983) The epidemiology of endometrial cancer in young women. Br. J. Cancer, 47, 749-756.
17. Weiss, N.S. and Sayvetz, T.A. (1980) Incidence of endometrial cancer in relation to the use of oral contraceptives. N. Engl. J. Med., 302, 551-554.
18. Grady, D. and Ernster, V.L. (1996) Endometrial cancer. In Shottenfeld, D. and Fraumeni, J.F. (eds) Cancer Epidemiology and Prevention. Oxford University Press, New York, NY, pp. 1180-1206.
19. Potischman, N., Hoover, R.N., Brinton, L.A. et al. (1996) Case-control study of endogenous hormones and endometrial cancer. J. Natl Cancer Inst., 88, 1127-1135.
20. Dao, T.L. (1981) The role of ovarian steroid hormones in mammary carcinogenesis. In Pike, M.C., Siiteri, P.K. and Welsch, C.W. (eds) Hormones and Breast Cancer. (Banbury Report no. 8). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 281-295.
21. Broocks, A., Pirke, K.M., Schweiger, U., Tuschl, R.J., Laessle, R.G., Strowitzki, T. et al. (1990) Cyclic ovarian function in recreational athletes. J. Appl. Physiol., 68, 2083-2086.
22. Bullen, B.A., Skrinar, G.S., Beitins, I.Z., von Mering, G., Turnbull, B.A. and McArthur, J.W. (1985) Induction of menstrual disorders by strenuous exercise in untrained women. N. Engl. J. Med., 312, 1349-1353.
23. Feicht, C.B., Johnson, T.S., Martin, B.J., Sparkes, K.E. and Wagner, W.W. Jr (1978) Secondary amenorrhea in athletes. Lancet, 2, 1145-1146.
24. Frisch, R.E., Wyshak, G. and Vincent, L. (1980) Delayed menarche and amenorrhea in ballet dancers. N. Engl. J. Med., 303, 17-19.
25. Bernstein, L., Henderson, B.E., Hanisch, R., Sullivan-Halley, J. and Ross, R.K. (1994) Physical exercise and reduced risk of breast cancer in young women. J. Natl Cancer Inst., 86, 1403-1408.
26. Thune, I., Brenn, T., Lunde, E. and Gaard, M. (1997) Physical activity and the risk of breast cancer. N. Engl. J. Med., 336, 1269-1275.
27. Rockhill, B., Willett, W.C., Hunter, D.J., Manson, J.E., Hankinson, S.E., Spiegelman, D. and Colditz, G.A. (1998) Physical activity and breast cancer risk in a cohort of young women. J. Natl Cancer Inst., 90, 1155-1160.
28. Smith-Warner, S., Spiegelman, D., Yaun, S.S. et al. (1998) Alcohol and breast cancer in women. A pooled analysis of cohort studies. J. Am. Med. Assoc., 279, 535-540.
29. Yu, H. (1998) Alcohol consumption and breast cancer risk. J. Am. Med. Assoc., 280, 1138-1139.
30. MacMahon, B., Cole, P., Brown, J.B. et al. (1974) Urine oestrogen profiles of Asian and North American women. Int. J. Cancer, 14, 161-167.
31. Bernstein, L., Yuan, J.M., Ross, R.K. et al. (1990) Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results form two breast cancer case-control studies. Cancer Causes Control, 1, 51-58.
32. Shimizu, H., Ross, R.K., Bernstein, L., Pike, M.C. and Henderson, B.E. (1990) Serum oestrogen levels in postmenopausal women: comparison of American whites and Japanese in Japan. Br. J. Cancer. 62, 451-453.
33. Thomas, H.V., Reeves, G.K. and Key, T.J.A. (1997) Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control, 8, 922-928.
34. Lipworth, L., Adami, H.O., Trichopoulos, D., Carlstrom, K. and Mantzoros, C. (1996) Serum steroid hormone levels, sex hormone-binding globulin and body mass index in the etiology of postmenopausal breast cancer Epidemiology, 7, 96-100.
35. Toniolo, P.G., Levitz, M., Zeleniuch-Jacquotte, A. et al. (1995) A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J. Natl Cancer Inst., 87, 190-197.
36. Berrino, F., Muti, P., Micheli, A. et al. (1996) Serum sex hormone levels after menopause and subsequent breast cancer. J. Natl Cancer Inst., 88, 291-296.
37. Thomas, H.V., Key, T.J., Allen, D.S., Moore, J.W., Dowsett, M., Fentiman, I.S. and Wang, D.Y. (1997) A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br. J. Cancer, 75, 1075-1079.
38. Thomas, H.V., Key, T.J., Allen, D.S., Moore, J.W., Dowsett, M., Fentiman, I.S. and Wang, D.Y. (1997) A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. Br. J. Cancer, 76, 401-405.
39. Dorgan, J.F., Longcope, C., Stephenson, H.E. et al. (1996) Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol. Biomarkers Prev., 5, 533-539.
40. Pike, M.C., Spicer, D.V., Dahmoush, L. and Press, M.F. (1993) Estrogens, progestogens, normal breast cell proliferation and breast cancer risk. Epidemiol. Rev., 15, 17-35.
41. Cline, J.M., Soderqvist, G., von Schoultz, E., Skoog, L. and von Schoultz, B. (1996) Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal macaques. Am. J. Obstet. Gynecol., 174, 93-100.
42. Feigelson, H.S. and Henderson, B.E. (1996) Estrogens and breast cancer. Carcinogenesis, 17, 2279-2284.
43. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet, 347, 1713-1727.
44. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet, 350, 1047-1059.
45. Laya, M.B., Larson, E.B., Taplin, S.H. and White, E. (1996) Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J. Natl Cancer Inst., 88, 643-649.
46. Brentano, S.T., Picado-Leonard, J., Mellon, S.H., Moore, C.C.D. and Miller, W.L. (1990) Tissue-specific cyclic adenosine 3′,5′-monophosphate-induced and phorbol ester-repressed transcription from the human P450c 17 promoter in mouse cells. Mol. Endocrinol., 4, 1972-1979.
47. Carey, A.H., Waterworth, D., Patel, K., White, D., Little, J., Novelli, P., Franks, S. and Williamson, R. (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum. Mol. Genet., 3, 1873-1876.
48. Feigelson, H.S., Coetzee, G.A., Kolonel, L.N., Ross, R.K. and Henderson, B.E. (1997) A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res., 57, 1063-1065.
49. Feigelson, H.S., Shames, L.S., Pike, M.C., Coetzee, G.A., Stanczyk, F.Z. and Henderson, B.E. (1998) CYP17 polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res., 58, 585-587.
50. Haiman, C.A., Hankinson, S.E., Spiegelman, D., Colditz, G.A., Willett, W.C., Speizer, F.E., Kelsey, K.T. and Hunter, D.J. (1999) The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res., 59, 1015-1020.
51. Dunning, A.M., Healey, C.S., Pharoah, P.D.P., Foster, N.A., Lipscombe, J.M., Redman, K.L., Easton, D.F., Day, N.E. and Ponder, B.A.J. (1998) No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br. J. Cancer, 77, 2045-2047.
52. Chern, H.D., Huang, C.S., Shen, C.Y., Cheng, C.W., Yang, S.Y. and Chang, K.J. (1998) Association of CYP7 with the susceptibility of breast cancer in Taiwan. Proceedings of the eighty-ninth annual meeting of the American Association for Cancer Research in cooperation with the Center for Continuing Education at Tulane University Medical Center. Cadmus Journal Services. Linthicum. MD, Vol. 39, p. 393.
53. Weston, A., Pan, C., Bleiweiss, I.J., Ksieski, H.B., Roy, N., Maloney, N. and Wolff, M.S. (1998) CYP17 genotype and breast cancer risk. Cancer Epidemiol. Biomarkers Prev., 7, 941-944.
54. Helzlsouer, K.J., Huang, H.Y., Strickland, P.T., Hoffman, S., Alberg, A.J., Comstock, G.W. and Bell, D.A. (1998) Association between CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol. Biomarkers Prev., 7, 945-949.
55. Ross, R.K. and Schottenfeld, D. (1996) Prostate cancer. In Shottenfeld, D. and Fraumeni, J.F. (eds) Cancer Epidemiology and Prevention. Oxford University Press, New York, NY, pp. 1180-1206.
56. Gann, P.H., Hennekens, C.H., Ma, J., Longcope, C. and Stampfer, M.J. (1996) Prospective study of sex hormone levels and risk of prostate cancer. J. Natl Cancer Inst., 88, 1118-1126.
57. Ross, R.K., Bernstein, L., Judd, H. et al. (1986) Serum testosterone levels in healthy young black and white men. J. Natl Cancer Inst., 76, 45-48.
58. Ross, R.K., Coetzee, G.A., Reichardt, J., Skinner, E. and Henderson, B.E. (1995) Does the racial-ethnic variation in prostate cancer risk have a hormonal basis? Cancer, 75, 1778-1782.
59. Makridakis, N., Ross, R.K., Pike, M.C., Chang, L., Stanczyk, F.Z., Kolonel, L.N., Shi, C.-Y., Yu, M.C., Henderson, B.E. and Reichardt, J.K.V. (1997) A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res., 57, 1020-1022.
60. Makridakis, N., Ross, R.K., Pike, M.C., Crocitto, L.E., Kolonel, L.N., Pearce, C.L., Henderson, B.E. and Reichardt, J.K.V. (1999) A missense substitution in the SRD5A2 gene is associated with prostate cancer in African-American and Latino men in Los Angeles. Lancet, 354, 975-978.
61. Ingles, S.A., Ross, R.K., Yu, M.C. Irvine, R.A., LaPera, G., Haile, R.W. and Coetzee, G.A. (1997) Association of prostate cancer risk with genetic polymorphism in vitamin D receptor and androgen receptor. J. Natl Cancer Inst., 89, 166-170.
62. Stanford, J.L., Just, J.J., Gibbs, M., Wicklund, K.G., Neal, C.L., Blumenstein, B.A. and Ostrander, E.A. (1997) Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res., 57, 1194-1198.
63. Giovannucci, E., Stampfer, M.J., Krithivas, K., Brown, M., Brufsky, A., Talcott, J., Hennekens, C.H. and Kantoff, P.W. (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl Acad. Sci. USA, 94, 3320-3323.
64. Hardy, D.O., Scher, H.I., Bogenreider, T., Sabbatini, P., Zhang, Z.F., Nanus, D.M. and Catterall, J.F. (1996) Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J. Clin. Endocrinol. Metab., 81, 4400-4405.
65. Hakimi, J.M., Schoenberg, M.P. RondinelliR, H., Piantadosi. S. and Barrack, E.R. (1997) Androgen receptor variants with short glutamine or glycine repeats identify unique subpopulations of men with prostate cancer. Clin. Cancer Res., 3, 1599-1608.
66. Fisher, B., Constantino, J.P., Wickerham, D.L. et al. (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J. Natl Cancer Inst., 90, 1371 -1388.
67. Cote, R.J., Skinner, E.C., Salem, C.E., Mertes, S.J., Stanczyk, F.Z., Henderson, B. E., Pike, M.C. and Ross, R.K. (1998) The effect of tinasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. Br J. Cancer, 78, 413-418.
68. Wingo, P.A., Tong, T. and Bolden, S. (1995) Cancer statistics 1995. CA Cancer J. Clin., 45, 8-30. [Erratum in CA Cancer J Clin., 45, 127-128.]